CardioSource WorldNews August 2015 | Page 37

PCSK9: It has

LDL receptors in
a serious bind
1

Recent discoveries show there’s an important new factor to consider. PCSK9 is a protein
that promotes degradation of the LDL receptor within hepatocytes, thereby increasing
plasma LDL-C levels.2,3 Amgen Cardiovascular is proud to be a leader in PCSK9 research
and remains dedicated to deepening our understanding of the critical role it plays
in cholesterol metabolism. PCSK9 means it’s time to discuss cholesterol differently.

Unite the cholesterol conversation at DiscoverPCSK9.com.

LDL = low-density lipoprotein; LDL-C = low-density lipoprotein cholesterol;
PCSK9 = proprotein convertase subtilisin/kexin type 9.
References: 1. Lambert G, Sjouke B, Choque B, Kastelein JJP, Hovingh GK. J Lipid Res. 2012;53:2515-2524.
2. Zhang D-W, Lagace TA, Garuti R, et al. J Biol Chem. 2007;282:18602-18612. 3. Qian YW, Schmidt RJ,
Zhang Y, et al. J Lipid Res. 2007;48(7):1488-1498.
© 2015 Amgen Inc. All Rights Reserved. Not for Reproduction. USA-145-101958